News
-
U.S. Clinical Laboratory Testing Sector Revenue To Jump To $63.8B By 2016
6/21/2012
TriMarkPublications.com cites in its newly published "Clinical Laboratory Testing Volume 2: Key Players for Laboratory Testing, Business Trends and Strategies" report that U.S. clinical laboratory testing sector revenue will jump to $63.8 billion by 2016.
-
HIV Vaccine Trials Network Opens Enrollment For Phase 1 Trial Of GeoVax Labs' Second Generation HIV Vaccine
5/22/2012
GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that the NIH-funded HIV Vaccine Trials Network (HVTN) has opened enrollment for a Phase 1 trial for the company's second-generation HIV vaccine.
-
Generex Announces New Members Of Antigen Express Scientific Advisory Board For The AE37 Breast Cancer Vaccine
5/17/2012
Generex Biotechnology Corporation (OTCBB: GNBT.OB) is pleased to announce today that new members have joined the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc. for the company's AE37 breast cancer vaccine.
-
Inovio Pharmaceuticals' Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses In Phase I Trial
5/16/2012
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its SynCon® avian influenza vaccine generated protective HAI titers against six different unmatched strains of H5N1 in a phase I clinical trial - a distinct clinical achievement on Inovio's path to develop universal influenza vaccines.
-
New Laboratory Technique Captures microRNA Targets
5/9/2012
Human cells are thought to produce thousands of different microRNAs (miRNAs)—small pieces of genetic material that help determine which genes are turned on or off at a given time.
-
MicuRx Pharmaceuticals Completes Phase 1 Trial For MRX-I, A Next-Generation Antibiotic
4/23/2012
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the completion of its Phase 1 clinical trial for MRX-I, its first development-stage antibiotic drug candidate.
-
Abbott Presents Positive Results From Phase 2 "Pilot" Study Of An Interferon-Free Combination Regimen For The Treatment Of Hepatitis C
4/19/2012
Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced complete data from the study known as "Pilot" – Abbott's initial interferon-free study of its direct-acting antiviral agents for the treatment of hepatitis C (HCV) – showing that 91 percent of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24).
-
Idaho Technology To Highlight Diagnostic FilmArray® Respiratory Panel At 28th Annual Clinical Virology Symposium
4/19/2012
Idaho Technology, Inc., a privately held clinical diagnostics company dedicated to providing the world's fastest, highest-quality instruments for pathogen identification and DNA analysis, today announced several posters will be presented highlighting its FilmArray® Respiratory Panel (FilmArray RP), a user-friendly Multiplex pathogen detection system, at the 28th Annual Clinical Virology Symposium and Annual Meeting of the Pan American Society for Clinical Virology, held April 22 - 25, 2012, in Daytona Beach, FL
-
Peregrine Launches PS-Targeting Clinical Imaging Program
4/4/2012
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that it has launched a program for its experimental phosphatidylserine (PS)-targeting molecular imaging candidate, 124I-PGN650, for the imaging of multiple solid tumor types.
-
AstraZeneca And Amgen Announce Collaboration To Jointly Develop And Commercialise Clinical-Stage Inflammation Portfolio
4/4/2012
AstraZeneca and Amgen recently announced an agreement to jointly develop and commercialise five monoclonal antibodies from Amgen’s clinical inflammation portfolio: AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827).